Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as well as the factors affecting loss to follow-up after anti-VEGF therapy.
The poster ‘Loss to Follow-Up in Patients With nAMD Treated With Anti-VEGF Therapy in the U.S.’ was presented at the annual American Academy of Ophthalmology (AAO) meeting, 30 September – 3 October 2022
- What is the impact of loss to follow up after anti-vascular endothelial growth factor (anti-VEGF) injections among patients with neovascular age-related macular degeneration (nAMD)? (00:19)
- What were the objectives and design of your study? (00:46)
- What were the overall findings of the study? (01:11)
- What factors affected loss to follow up? (02:19)
- What interventions may improve outcomes? (02:50)
Disclosure: Rahul Khurana has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of AAO 2022.
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!